Cellares Secures $255M Series to Launch Innovative IDMO and Smart Factory for Life-Saving Cell Therapies
Introduction:
Cellares, an industry leader in Integrated Development and Manufacturing Organizations (IDMO) focused on cell therapy, is positioned to address the increasing global demand for cell therapies with its ambitious global Smart Factory expansion plans.
Features:
This substantial funding injection will play a pivotal role in the initiation of the world's inaugural commercial-scale IDMO Smart Factory, strategically situated in Bridgewater, New Jersey, and encompassing an expansive 118,000 sq. ft.
Demonstrating an impressive capacity to produce 40,000 cell therapy batches annually, this state-of-the-art facility harnesses advanced robotics, tailor-made technology, and seamlessly interconnected software.
Remarkably, Cellares IDMO Smart Factory achieves a remarkable tenfold increase in cell therapy batch production compared to traditional facilities, all within the same spatial and workforce parameters.
Cellares versatile manufacturing technology is adaptable to both autologous and allogeneic cell therapy processes, encompassing nearly 90% of cell therapy modalities.
The Bridgewater, New Jersey site, dedicated to commercial-scale manufacturing, is projected to attain cGMP readiness by the latter half of 2024 and offers ample space for 50 Cell Shuttles.
Furthermore, the South San Francisco Smart Factory is on track to achieve cGMP readiness in the initial half of 2024, further enhancing Cellares manufacturing capabilities.
Specifications:
Name: Cellares
Type: Construction
Year: 2024
